MedTrace Logo

Investigating the Morbidity of Glucocorticoid Use in Patients With Autoimmune Bullous Diseases (AIBDs)

NCT05525065 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 138

Last updated 2023-08-31

No results posted yet for this study

Summary

This project utilised the validated glucocorticoid toxicity index (GTI) tool to assess the morbidity of glucocorticoid-use in patients with autoimmune bullous disease. In particular, the study investigated the nature and prevalence of glucocorticoid-induced myopathy.

Conditions

  • Autoimmune Bullous Dermatosis
  • Glucocorticoids Toxicity

Interventions

DRUG

GlucoCorticoid

Glucocorticoid as calculated in prednisone oral equivalents.

Sponsors & Collaborators

  • Steritas

    collaborator UNKNOWN

  • Premier Specialists, Australia

    lead OTHER

Principal Investigators

  • Dedee Murrell, MBBS · University of New South Wales

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-02
Primary Completion
2023-09-01
Completion
2025-09-01

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05525065 on ClinicalTrials.gov